TNYA - Tenaya Therapeutics, Inc.
IEX Last Trade
1.64
-0.035 -2.134%
Share volume: 67,069
Last Updated: Thu 26 Dec 2024 08:29:36 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$1.68
-0.04
-2.09%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
4.40%
1 Month
-49.54%
3 Months
-17.82%
6 Months
-38.97%
1 Year
-47.96%
2 Year
-1.19%
Key data
Stock price
$1.64
DAY RANGE
$1.56 - $1.68
52 WEEK RANGE
$1.41 - $7.01
52 WEEK CHANGE
-$51.03
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Faraz Ali
Region: US
Website: tenayatherapeutics.com
Employees: 110
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: tenayatherapeutics.com
Employees: 110
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Tenaya Therapeutics, Inc. discovers, develops, and delivers therapies for heart disease in the United States. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) and gDCM. It is also developing a small molecule inhibitor of histone deacetylase 6 for use in heart failure with preserved ejection fraction (HFpEF)
Recent news